Regulation
AngioDynamics reports PRESERVE trial results for NanoKnife system
AngioDynamics released two-year data from its PRESERVE pivotal trial demonstrating durable outcomes for the NanoKnife irreversible electroporation (IRE) system in intermediate-risk prostate cancer treatment. The trial results support the clinical profile of the device and may inform future regulatory submissions or label claims for the platform.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network